Medindia3d
Non-Invasive ctDNA Testing for Early Detection of Multiple Myeloma
Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire ...
"There’s No Cure Without Us”: One Woman’s Mission To Transform Awareness And Care For Black Patients With Multiple Myeloma
After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...
Rolling Out5d
A rare cancer, modified cells, and the future they promised
A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...
This Couple Talks About Navigating a Rare Blood Cancer as a Team
From uncertainty to hope for the future, they offer advice on getting through some of the toughest years of their lives ...
pharmaphorum1d
Driving innovation in multiple myeloma to improve the patient experience
Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...
Active Biotech AB: First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis
Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis ...
Penn-made AI tool matched a patient’s rare disease with a common inflammation drug. He’s been in remission for over two years.
Every Cure was co-founded by a Penn immunologist after discovering an off-label treatment for his own rare disease.
pharmaphorum6d
FDA approves GSK's Blenrep for advanced multiple myeloma
The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep ... corneal ulcer and symptoms such as blurred vision and dry eyes. Ocular adverse reactions occurred in 77% of the 218 ...